These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8583988)

  • 1. [Anti-angiogenesis: a new concept in therapy of solid malignancies?].
    Schweigerer L
    Med Klin (Munich); 1995 Dec; 90(12):709-12. PubMed ID: 8583988
    [No Abstract]   [Full Text] [Related]  

  • 2. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing the delivery of cancer drugs that block angiogenesis.
    Cao Y; Langer R
    Sci Transl Med; 2010 Jan; 2(15):15ps3. PubMed ID: 20371469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis research: guidelines for translation to clinical application.
    Folkman J; Browder T; Palmblad J
    Thromb Haemost; 2001 Jul; 86(1):23-33. PubMed ID: 11487011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of tumor vascularization.
    Auguste P; Lemiere S; Larrieu-Lahargue F; Bikfalvi A
    Crit Rev Oncol Hematol; 2005 Apr; 54(1):53-61. PubMed ID: 15780907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Closing in on cancer.
    Park A
    Time; 2001 May; 157(20):60, 62. PubMed ID: 11383110
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and antiangiogenic therapy in hematologic malignancies.
    Dong X; Han ZC; Yang R
    Crit Rev Oncol Hematol; 2007 May; 62(2):105-18. PubMed ID: 17188504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis: the unifying concept in cancer?
    Saphir A
    J Natl Cancer Inst; 1997 Nov; 89(22):1658-9. PubMed ID: 9390530
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiangiogenic therapy at a crossroads: clinical trial results and future directions.
    Ellis LM
    J Clin Oncol; 2003 Dec; 21(23 Suppl):281s-283s. PubMed ID: 14645411
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiogenesis in cancer.
    Juczewska M; Chyczewski L
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():86-100. PubMed ID: 9337527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of angiogenesis in the treatment of tumors.
    Ostrowski K; Kinsner A
    Arch Immunol Ther Exp (Warsz); 2001; 49(1):27-31. PubMed ID: 11266087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiogenesis and its inhibitors].
    Ono M; Kuwano M
    Gan To Kagaku Ryoho; 1997 Sep; 24(11):1585-93. PubMed ID: 9309158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of angiogenesis inhibitors in tumour treatment.
    Fayette J; Soria JC; Armand JP
    Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiogenesis as a target for antitumor actions].
    Ushmorov AG; Aleksandrov VA
    Vopr Onkol; 1989; 35(3):263-70. PubMed ID: 2468258
    [No Abstract]   [Full Text] [Related]  

  • 18. Recognition of tumor blood vessel normalization as a new antiangiogenic concept.
    Hellmann K
    Nat Med; 2004 Apr; 10(4):329; author reply 329-30. PubMed ID: 15057218
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999).
    d'Onofrio A; Gandolfi A
    Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taking down tumors: vascular disrupting agents entering clinical trials.
    O'Hanlon LH
    J Natl Cancer Inst; 2005 Sep; 97(17):1244-5. PubMed ID: 16145041
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.